Drugs / MVC-COV1901(Beta)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05216601 | May → Jul 2022 | — | Medigen Vaccine Biologics Corp. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVC-COV1901(Beta) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05216601 ↗ |
| Modality | Vaccine | “SARS-CoV-2 Vaccine” NCT05216601 ↗ |
| Route | Intramuscular | “via intramuscular (IM) injection in the deltoid region” NCT05216601 ↗ |